CBP-1019

DRUG2 trials

Sponsors

Coherent Biopharma (Hefei) Co., Ltd., M.D. Anderson Cancer Center

Conditions

Cancer ColorectalCancer of EsophagusCancer of PancreasCancer, BreastCancer, LungSolid Tumor

Phase 1

A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors

Coherent Biopharma (Hefei) Co., Ltd.Cancer, Breast, Cancer Colorectal, Cancer, Lung +2

Start: 2023-03-14End: 2025-09-30Target: 260Updated: 2024-08-26

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

RecruitingNCT06576037

M.D. Anderson Cancer CenterSolid Tumor

Start: 2024-10-31End: 2029-06-01Target: 128Updated: 2026-09-01